COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Tiago Rama (Author) FMUP; Miranda, J (Author) Other; Silva, D (Author) FMUP; Amaral, L (Author) Other; Castro, E (Author) Other; Coimbra, A (Author) Other; Moreira, André (Author) FMUP; Placido, JL (Author) Other

Journal

Title: Vaccines

Vol. 10

Final page: 718

ISSN: 2076-393X

Indexing

ISI Web of Knowledge - 7 Citations

Scopus - 9 Citations

Other information

Authenticus ID: P-00W-FPN

DOI: 10.3390/vaccines10050718

Abstract (EN): Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders-a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed to assess the safety of COVID-19 vaccines in patients with clonal MC disorders. We performed an ambidirectional cohort study with 30 clonal MC disorder patients (n = 26 in the prospective arm and n = 4 in the retrospective arm), that were submitted to COVID-19 vaccination. Among these, 11 (37%) were males, and median age at vaccination date was 41 years (range: 5y to 76y). One patient had prior history of anaphylaxis following vaccination. Those in the prospective arm received a premedication protocol including H1- and H2-antihistamines and montelukast, while those in the retrospective arm did not premedicate. Overall, patients received a total of 81 doses, 73 under premedication and 8 without premedication. No MC activation symptoms were reported. COVID-19 vaccination seems to be safe in patients with clonal mast cell disorders, including those with prior anaphylaxis following vaccination. Robust premedication protocols may allow for vaccination in ambulatory settings.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9